Internal Medicine
Online ISSN : 1349-7235
Print ISSN : 0918-2918
ISSN-L : 0918-2918
CASE REPORTS
Stringent Complete Remission of Primary Plasma Cell Leukemia with Reduced-dose Bortezomib, Lenalidomide and Dexamethasone: A Case Report and Review of the Literature
Shuji UedaMasahiko KuboNoriko MatsuuraHitomi MatsunagaSeiko KataokaTetsuo MaedaYoshiaki InuiSumio KawataYuzuru Kanakura
Author information
JOURNALS OPEN ACCESS

2013 Volume 52 Issue 11 Pages 1235-1238

Details
Abstract

Plasma cell leukemia (PCL) is an aggressive variant of multiple myeloma characterized by a high level of plasma cells circulating in the peripheral blood. The prognosis of PCL patients treated with conventional chemotherapy remains poor. Some reports have suggested that both bortezomib and lenalidomide are effective in treating PCL. We herein report a case of primary PCL in which the patient achieved stringent complete remission after receiving combination chemotherapy with reduced-dose bortezomib, lenalidomide and dexamethasone (VRd). This regimen was very effective, and no severe adverse events were observed. A reduced-dose VRd regimen can be considered in PCL patients.

Information related to the author
© 2013 by The Japanese Society of Internal Medicine
Previous article Next article
feedback
Top